FDA approves Genentech’s Vabysmo Prefilled Syringe (PFS) for three leading causes of vision loss Read more
FDA grants BTD for Venclexta in combination with azacitidine to treat patients with myelodysplastic syndromes Read more
US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive MS Read more
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers Read more
Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia Read more